On Jan 28, 2021, Mammoth Biosciences announced a co-marketing agreement with Agilent Technologies to support the anticipated launch of a complete CRISPR-based SARS-CoV-2 diagnostic solution comprising Agilentﾒs Bravo automation workstation and Mammoth Biosciencesﾒ DETECTR BOOSTTM assay.